Literature DB >> 26228539

Mirtazapine toxicity in cats: retrospective study of 84 cases (2006-2011).

Leah E Ferguson1, Mary Kay McLean2, Julia A Bates3, Jessica M Quimby1.   

Abstract

Objectives Mirtazapine is commonly used in veterinary medicine at doses of 1.88 or 3.75 mg as an appetite stimulant. The objectives of this study were to determine the most common adverse effects reported and the dose associated with these signs. Methods Records of cats with mirtazapine exposure (2006-2011) were obtained from the American Society for the Prevention of Cruelty to Animals' Animal Poison Control Center. The following parameters were recorded: signalment, weight, outcome, agent ingested, amount ingested, route of exposure, clinical signs observed, intended of use, onset time of signs and duration of signs. Results The 10 most commonly observed adverse effects reported in 84 cats exposed to mirtazapine included vocalization (56.0% of cats; mean dose 2.56 mg/kg), agitation (31.0%; 2.57 mg/kg), vomiting (26.2%; 2.92 mg/kg), abnormal gait/ataxia (16.7%; 2.87 mg/kg), restlessness (14.3%; 3.55 mg/kg), tremors/trembling (14.3%; 2.43 mg/kg), hypersalivation (13.0%; 2.89 mg/kg), tachypnea (11.9%; 3.28 mg/kg), tachycardia (10.7%; 3.04 mg/kg) and lethargy (10.7%; 2.69 mg/kg). Fifty-nine (70.2%) cases were considered accidental ingestions and 25 (29.8%) cases were given mirtazapine as prescribed. The doses associated with signs of toxicity were 15.00 mg (40 cats), 3.75 mg (25 cats), 7.50 mg (four cats), 30.00 mg (one cat), 18.75 mg (one cat), 11.25 mg (one cat), 5.80 mg (one cat) and 1.88 mg (one cat). For cats with available information, the onset of clinical signs ranged from 15 mins to 3 h, and time to resolution of clinical signs ranged from 12-48 h. Conclusions and relevance The greater number of adverse effects at 3.75 mg rather than 1.88 mg suggests that the latter may be a more appropriate starting dose for stimulating appetite while limiting toxicity. The benefit of dispensing exact doses of mirtazapine is implied given the likelihood of accidental administration of a full tablet (15 mg) and the resulting toxicity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26228539     DOI: 10.1177/1098612X15599026

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  5 in total

1.  A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.

Authors:  Melinda Poole; Jessica M Quimby; Tianhua Hu; Daizie Labelle; William Buhles
Journal:  J Vet Pharmacol Ther       Date:  2018-12-02       Impact factor: 1.786

2.  Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease.

Authors:  Jessica M Quimby; Kellyi K Benson; Stacie C Summers; Ashlie Saffire; Andrea K Herndon; Shasha Bai; Daniel L Gustafson
Journal:  J Feline Med Surg       Date:  2019-06-04       Impact factor: 2.015

3.  ACVIM consensus statement on pancreatitis in cats.

Authors:  Marnin A Forman; Joerg M Steiner; P Jane Armstrong; Melinda S Camus; Lorrie Gaschen; Steve L Hill; Caroline S Mansfield; Katja Steiger
Journal:  J Vet Intern Med       Date:  2021-02-15       Impact factor: 3.333

Review 4.  Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease.

Authors:  Francesca De Santis; Andrea Boari; Francesco Dondi; Paolo Emidio Crisi
Journal:  Animals (Basel)       Date:  2022-01-21       Impact factor: 2.752

5.  Appetite Stimulant and Anti-Emetic Effect of Mirtazapine Transdermal Ointment in Cats Affected by Lymphoma Following Chemotherapy Administration: A Multi-Centre Retrospective Study.

Authors:  Livia Ferro; Stefano Ciccarelli; Giacomo Stanzani; Lisa Nappi; Francesca Angelini; Chiara Leo
Journal:  Animals (Basel)       Date:  2022-01-09       Impact factor: 2.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.